Sep 14 |
Vaxcyte, Inc. (PCVX): Among Hedge Funds’ Top Biotech Stock Picks
|
Sep 11 |
Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference
|
Sep 8 |
Vaxcyte's Broad-Spectrum Pneumococcal Vaccines Poised For Market Dominance By 2027
|
Sep 6 |
Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
|
Sep 6 |
Vaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy
|
Sep 6 |
Obesity drug startup raises $67M; Vor’s ‘shielded transplant’ shows promise
|
Sep 5 |
Vaxcyte prices $1.3B equity offering
|
Sep 5 |
Vaxcyte Announces Pricing of $1.3 Billion Public Offering
|
Sep 4 |
Vaxcyte Stock Hits Record High on Pneumococcal Vaccine Study Results
|
Sep 4 |
Company News for Sep 4, 2024
|